粒细胞集落刺激因子改善适合激素治疗的严重酒精相关性肝炎患者的泼尼松龙反应性和90天生存率:GPreAH随机试验
联合治疗组90天生存率、第7天应答率更高, discriminant function 和 MELDNa 改善更明显,新发感染、急性肾损伤、肝性脑病和再住院率更低。
要点
- 联合组90天生存率88.1%,高于泼尼松龙组的64.3%(P=0.03)。
- 联合组第7天应答率92.9%,高于泼尼松龙组的71.4%和单用粒细胞集落刺激因子组的76.2%(P=0.037)。
- 联合组新发感染率19%,低于泼尼松龙组的35.7%(P<0.002)。
核心结论
- 在泼尼松龙基础上加用粒细胞集落刺激因子可改善严重酒精相关性肝炎患者的激素反应性和90天生存率,并减少感染和新发并发症。
研究设计与样本
- 随机试验纳入符合激素治疗条件的严重酒精相关性肝炎患者(判别函数评分32-90),随机分为泼尼松龙组(n=42)、联合组(n=42)和单用粒细胞集落刺激因子组(n=42)。
- 粒细胞集落刺激因子按150-300 mcg/d给药7天,之后每3天一次,1个月内最多12次;泼尼松龙40 mg/d给药7天,应答者(Lille评分<0.45)继续至28天。
主要发现
- 意向性治疗分析中,90天生存率泼尼松龙组64.3%(27/42)、联合组88.1%(37/42)、单用粒细胞集落刺激因子组78.6%(33/42),泼尼松龙组与联合组比较P=0.03。
- 28天生存率三组分别为85.7%、95.2%、85.7%(P=0.27),组间无显著差异。
- 第7天应答率三组分别为71.4%、92.9%、76.2%(P=0.037)。
- 第90天判别函数变化三组分别为-7.33±4.78、-24.59±3.7、-14.59±3.41(P=0.011);MELDNa变化分别为-1.69±1.26、-7.02±1.24、-3.05±0.83(P=0.002)。
- 新发感染率三组分别为35.7%、19%、7.1%(P<0.002);急性肾损伤率分别为33.3%、7.1%、11.9%(P=0.002);肝性脑病率分别为35.7%、9.5%、26.2%(P<0.001);再住院率分别为59.5%、14.3%、30.9%(P<0.01)。
临床怎么用
- 作者认为,在泼尼松龙基础上加用粒细胞集落刺激因子可改善严重酒精相关性肝炎患者的激素反应性和90天生存率,并减少感染和新发并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Severe alcohol-associated hepatitis (SAH) carries high 1-month mortality. Corticosteroids provide a modest 28-day but not 90-day survival benefit, due to development of infections and organ failures. Granulocyte colony-stimulating factor (GCSF) has shown promise in patients with SAH by its immunomodulatory and regenerative capabilities. We studied the safety and efficacy of combination (GCSF + prednisolone, GPred) therapy in management of steroid-eligible patients with SAH. METHODS: Steroid eligible patients with SAH (discriminant function scores 32-90) were randomized to receive prednisolone (GrA, n = 42), GPred (GrB, n = 42), or GCSF alone (GrC, n = 42). GCSF was given as 150-300 mcg/d for 7 days followed by every third day for a maximum of 12 doses in 1 month. Prednisolone 40 mg/d was given for 7 days and continued for 28 days in responders (Lille score <0.45). RESULTS: Baseline characteristics of patient groups were comparable. On intention-to-treat analysis, the primary endpoint of 90-day survival was achieved in 64.3% (27/42) in prednisolone, 88.1% (37/42) in GPred, and 78.6%(33/42) in GCSF groups, respectively ( P = 0.03, prednisolone vs GPred). The 28-day survival was not different between the groups (85.7%, 95.2%, and 85.7%, respectively [ P = 0.27]). The GPred group had more responders by day 7 (71.4% vs 92.9% vs 76.2%, P = 0.037) and had greater reduction in discriminant function (-7.33 ± 4.78, -24.59 ± 3.7, -14.59 ± 3.41, P = 0.011) and MELDNa (-1.69 ± 1.26, -7.02 ± 1.24, -3.05 ± 0.83, P = 0.002) by day 90. The prednisolone-only group had higher incidence of new infections (35.7%, 19%, 7.1%, respectively, P < 0.002). Acute kidney injury (33.3%, 7.1%, 11.9%, P = 0.002), hepatic encephalopathy (35.7%, 9.5%, 26.2%, P = <0.001), and rehospitalizations (59.5%, 14.3%, 30.9%, P =<0.01) were lower in the GPred group. CONCLUSION: Addition of GCSF to prednisolone improves steroid responsiveness and 90-day survival with fewer infections and new onset complications in patients with SAH.
引用
- Mishra AK, Shasthry SM, Vijayaraghavan R, et al. Granulocyte Colony-Stimulating Factor Improves Prednisolone Responsiveness and 90-Day Survival in Steroid-Eligible Severe Alcohol-Associated Hepatitis: The GPreAH Study a Randomized Trial. Am J Gastroenterol. 2024. PMID: 39162744. doi:10.14309/ajg.0000000000003038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。